193 related articles for article (PubMed ID: 10219466)
1. Pharmacokinetics of latanoprost in the cynomolgus monkey. 1st communication: single intravenous, oral or topical administration on the eye.
Sjöquist B; Tajallaei S; Stjernschantz J
Arzneimittelforschung; 1999 Mar; 49(3):225-33. PubMed ID: 10219466
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of latanoprost in the cynomolgus monkey. 2nd communication: repeated topical administration on the eye.
Sjöquist B; Uhlin A; Byding P; Stjernschantz J
Arzneimittelforschung; 1999 Mar; 49(3):234-9. PubMed ID: 10219467
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of latanoprost in the cynomolgus monkey. 3rd communication: tissue distribution after topical administration on the eye studied by whole body autoradiography. Glaucoma Research Laboratories.
Sjöquist B; Johansson A; Stjernschantz J
Arzneimittelforschung; 1999 Mar; 49(3):240-9. PubMed ID: 10219468
[TBL] [Abstract][Full Text] [Related]
4. The pharmacokinetics of a new antiglaucoma drug, latanoprost, in the rabbit.
Sjöquist B; Basu S; Byding P; Bergh K; Stjernschantz J
Drug Metab Dispos; 1998 Aug; 26(8):745-54. PubMed ID: 9698288
[TBL] [Abstract][Full Text] [Related]
5. Disposition and metabolism of a novel prostanoid antiglaucoma medication, tafluprost, following ocular administration to rats.
Fukano Y; Kawazu K
Drug Metab Dispos; 2009 Aug; 37(8):1622-34. PubMed ID: 19477946
[TBL] [Abstract][Full Text] [Related]
6. Ocular and systemic pharmacokinetics of latanoprost in humans.
Sjöquist B; Stjernschantz J
Surv Ophthalmol; 2002 Aug; 47 Suppl 1():S6-12. PubMed ID: 12204697
[TBL] [Abstract][Full Text] [Related]
7. Metabolism and ocular tissue distribution of an antiglaucoma prostanoid, tafluprost, after ocular instillation to monkeys.
Fukano Y; Kawazu K; Akaishi T; Bezwada P; Pellinen P
J Ocul Pharmacol Ther; 2011 Jun; 27(3):251-9. PubMed ID: 21491995
[TBL] [Abstract][Full Text] [Related]
8. Effect of 15-keto latanoprost on intraocular pressure and aqueous humor dynamics in monkey eyes.
Wang RF; Gagliuso DJ; Mittag TW; Podos SM
Invest Ophthalmol Vis Sci; 2007 Sep; 48(9):4143-7. PubMed ID: 17724199
[TBL] [Abstract][Full Text] [Related]
9. Microvascular effects of selective prostaglandin analogues in the eye with special reference to latanoprost and glaucoma treatment.
Stjernschantz J; Selén G; Astin M; Resul B
Prog Retin Eye Res; 2000 Jul; 19(4):459-96. PubMed ID: 10785618
[TBL] [Abstract][Full Text] [Related]
10. Oral and topical absorption, disposition kinetics, and the metabolic fate of trans-methyl styryl ketone in the male Fischer 344 rat.
Sauer JM; Smith RL; Bao J; Kattnig MJ; Kuester RK; McClure TD; Mayersohn M; Sipes IG
Drug Metab Dispos; 1997 Jun; 25(6):732-9. PubMed ID: 9193875
[TBL] [Abstract][Full Text] [Related]
11. Latanoprost systemic exposure in pediatric and adult patients with glaucoma: a phase 1, open-label study.
Raber S; Courtney R; Maeda-Chubachi T; Simons BD; Freedman SF; Wirostko B;
Ophthalmology; 2011 Oct; 118(10):2022-7. PubMed ID: 21788077
[TBL] [Abstract][Full Text] [Related]
12. The ocular effects of prostaglandins and the therapeutic potential of a new PGF2 alpha analog, PhXA41 (latanoprost), for glaucoma management.
Bito LZ; Stjernschantz J; Resul B; Miranda OC; Basu S
J Lipid Mediat; 1993; 6(1-3):535-43. PubMed ID: 8358014
[TBL] [Abstract][Full Text] [Related]
13. Absorption, distribution and excretion of [carbonyl-14C]mosapride citrate after a single oral administration in rats, dogs and monkeys.
Matsumoto S; Tagawa M; Amejima H; Nakao M; Kagemoto A; Fujii T; Miyazaki H; Sekine Y
Arzneimittelforschung; 1993 Oct; 43(10):1084-94. PubMed ID: 8267675
[TBL] [Abstract][Full Text] [Related]
14. Ocular absorption, distribution, and systemic absorption of a novel antiglaucoma medication, prostaglandin derivative, in male white rabbits.
Higaki K; Kamata K; Takeuchi M; Inazawa K; Chikai T; Hamaguchi T; Yukawa T; Kadono K; Kawahara S; Nakano M
Drug Metab Dispos; 1995 Jan; 23(1):35-43. PubMed ID: 7720522
[TBL] [Abstract][Full Text] [Related]
15. Topical and oral ketorolac administration increases the intraocular pressure-lowering effect of latanoprost.
Costagliola C; Campa C; Perri P; Parmeggiani F; Romano MR; Incorvaia C
Curr Eye Res; 2008 May; 33(5):477-82. PubMed ID: 18568885
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and metabolism of the prodrug DB289 (2,5-bis[4-(N-methoxyamidino)phenyl]furan monomaleate) in rat and monkey and its conversion to the antiprotozoal/antifungal drug DB75 (2,5-bis(4-guanylphenyl)furan dihydrochloride).
Midgley I; Fitzpatrick K; Taylor LM; Houchen TL; Henderson SJ; Wright SJ; Cybulski ZR; John BA; McBurney A; Boykin DW; Trendler KL
Drug Metab Dispos; 2007 Jun; 35(6):955-67. PubMed ID: 17360833
[TBL] [Abstract][Full Text] [Related]
17. Effects of topical latanoprost on optic nerve head circulation in rabbits, monkeys, and humans.
Ishii K; Tomidokoro A; Nagahara M; Tamaki Y; Kanno M; Fukaya Y; Araie M
Invest Ophthalmol Vis Sci; 2001 Nov; 42(12):2957-63. PubMed ID: 11687542
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of prulifloxacin. 1st communication: absorption, distribution and excretion in rats, dogs and monkeys after a single administration.
Okuyama Y; Momota K; Morino A
Arzneimittelforschung; 1997 Mar; 47(3):276-84. PubMed ID: 9105546
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of NS-105, a novel cognition enhancer. 1st communication: absorption, metabolism and excretion in rats, dogs and monkeys after single administration of 14C-NS-105.
Mukai H; Sugimoto T; Ago M; Morino A
Arzneimittelforschung; 1999 Nov; 49(11):881-90. PubMed ID: 10604039
[TBL] [Abstract][Full Text] [Related]
20. Metabolism and pharmacokinetics of a double prodrug of ganciclovir in the rat and monkey.
Krasny HC; Beauchamp L; Krenitsky TA; de Miranda P
Drug Metab Dispos; 1995 Nov; 23(11):1242-7. PubMed ID: 8591725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
